CAJ | 학술논문

目的：探究喘可治注射液辅助治疗非小细胞肺癌的临床疗效及对T淋巴细胞亚群的影响。方法选择2010年7月—2014年9月在新疆维吾尔自治区胸科医院接受治疗的102例非小细胞肺癌患者，采用随机数字表法将患者分为对照组和观察组，每组51例。对照组患者采用GP化疗方案（顺铂＋吉西他滨）治疗，观察组在对照组治疗基础上联合喘可治注射液辅助治疗。比较两组患者临床疗效及毒副作用，治疗前后T淋巴细胞亚群（ CD3＋细胞分数、CD4＋细胞分数、 CD8＋细胞分数以及CD4＋／CD8＋细胞比值）、 QLQ－C30量表评分（主要包括社会功能、情绪功能、躯体功能以及整体生活质量4个方面）。结果观察组患者临床疗效优于对照组（ u＝2.534， P＝0.011）。治疗前两组患者CD3＋细胞分数、 CD4＋细胞分数、 CD8＋细胞分数、 CD4＋／CD8＋细胞比值比较，差异无统计学意义（ P＞0.05）；治疗后观察组患者CD3＋细胞分数、 CD4＋细胞分数、 CD4＋／CD8＋细胞比值均高于对照组（ P＜0.01）。治疗前两组患者社会功能、情绪功能、躯体功能以及整体生活质量评分比较，差异无统计学意义（ P＞0.05）；治疗后观察组患者社会功能、情绪功能、躯体功能以及整体生活质量评分均高于对照组（P＜0.01）。观察组患者白细胞计数（WBC）减少、血小板计数（ PLT）减少、血红蛋白（ HGB）水平降低及恶心呕吐发生率均低于对照组（ P＜0.05）。结论喘可治注射液辅助治疗非小细胞肺癌的临床疗效确切，能有效提高患者免疫功能，改善患者生活质量，且毒副作用较少。
목적：탐구천가치주사액보조치료비소세포폐암적림상료효급대T림파세포아군적영향。방법선택2010년7월—2014년9월재신강유오이자치구흉과의원접수치료적102례비소세포폐암환자，채용수궤수자표법장환자분위대조조화관찰조，매조51례。대조조환자채용GP화료방안（순박＋길서타빈）치료，관찰조재대조조치료기출상연합천가치주사액보조치료。비교량조환자림상료효급독부작용，치료전후T림파세포아군（ CD3＋세포분수、CD4＋세포분수、 CD8＋세포분수이급CD4＋／CD8＋세포비치）、 QLQ－C30량표평분（주요포괄사회공능、정서공능、구체공능이급정체생활질량4개방면）。결과관찰조환자림상료효우우대조조（ u＝2.534， P＝0.011）。치료전량조환자CD3＋세포분수、 CD4＋세포분수、 CD8＋세포분수、 CD4＋／CD8＋세포비치비교，차이무통계학의의（ P＞0.05）；치료후관찰조환자CD3＋세포분수、 CD4＋세포분수、 CD4＋／CD8＋세포비치균고우대조조（ P＜0.01）。치료전량조환자사회공능、정서공능、구체공능이급정체생활질량평분비교，차이무통계학의의（ P＞0.05）；치료후관찰조환자사회공능、정서공능、구체공능이급정체생활질량평분균고우대조조（P＜0.01）。관찰조환자백세포계수（WBC）감소、혈소판계수（ PLT）감소、혈홍단백（ HGB）수평강저급악심구토발생솔균저우대조조（ P＜0.05）。결론천가치주사액보조치료비소세포폐암적림상료효학절，능유효제고환자면역공능，개선환자생활질량，차독부작용교소。
Objective To investigate the clinical effect of chuankezhi injection in the adjuvant treatment of non-small cell lung cancer and its impact on T-lymphocyte subsets.Methods A total of 102 patients with non-small cell lung cancer were selected in the Chest Hospital of Xinjiang Uygur Autonomous Region from July 2010 to September 2014, and they were divided into control group and observation group according to random number table, each of 51 cases.Patients of both groups received GP chemotherapy regimens ( cisplatin combined with gemcitabine) , while patients of observation group received extra chuankezhi injection. Clinical effect, incidence of toxic and side effect, T -lymphocyte subsets ( including CD3+ cell percentage, CD4+cell percentage, CD8+ cell percentage and CD4+/CD8+ cell ratio ) and QLQ -C30 score ( including social function, emotional function, physical function and global quality of life) before and after treatment were compared between the two groups.Results the clinical effect of observation group was statistically significantly better than that of control group ( u=2.534, P=0.011).No statistically significant differences of CD3+cell percentage, CD4+cell percentage, CD8+cell percentage or CD4+/CD8+cell ratio was found between the two groups before treatment, while CD3+cell percentage, CD4+cell percentage and CD4+/CD8+cell ratio of observation group were statistically significantly higher than those of control group ( P <0.01 ) . No statistically significant differences of social function score, emotional function score, physical function score or global quality of life score was found between the two groups before treatment (P>0.05), while above index of observation group was statistically significantly higher than that of control group, respectively ( P<0.01 ) .The incidence of decreased WBC, decreased PLT, decreased HGB level, nausea and vomiting of observation group was statistically significantly lower than that of control group, respectively (P<0.05).Conclusion Chuankezhi injection has certain clinical effect in the adjuvant treatment of non-small cell lung cancer, which can effectively improve the immunologic function and quality of life with less toxic and side effect.